Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Analysis Of Expression Of Programmed Cell Death 1 Ligand 1 (PD-L1) In Malignant Pleural Mesothelioma (MPM)
S. Cedrés, S. Ponce-Aix, J. Zugazagoitia, I. Sansano, A. Enguita, A. Navarro-Mendivil, A. Martínez-Martí, P. Martínez, E. Felip
Published 2015 · Biology, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Background The increasing incidence and poor outcome associated with MPM requires finding effective treatment for this disease. PD1/PD-L1 pathway plays a central role in tumor immune evasion and appears to be predictive and prognostic marker. PD-L1 is expressed in many different human cancers but its role in MPM has yet to be established. The aim of this study is to evaluate the expression of PD-L1 in MPM. Methods 119 MPM patients (p) from two institutions between November 2002 and February 2014 were reviewed. Formalin-fixed, paraffin-embedded tissue was stained with anti-PD-L1 (clone E1L3N). Cases showing more than 1% of tumor cells expression of PD-L1 were considered positive. Results PD-L1 was analyzed in 77 p with tumor tissue available and was positive in 20.7% p (14 samples in membrane, 16 in cytoplasm and 4 in immune infiltrate). PD-L1 intensity was weak in 56.2%, moderate in 25% and strong in 18.7% p. There was a significant relationship between PD-L1 expression and histology (PD-L1 expression 37.5% in no-epithelioid tumor and 13.2% in epithelioid; p=0.033). The median survival in p PD-L1 positive was 4.79 vs 16.3 months in p PD-L1 negative (p=0.012). Conclusions We have shown PD-L1 is expressed in 20% of patients, associated with no epithelioid histology and poor prognostic in MPM. Our results suggest PD-L1 warrants further exploration in selecting p for immunotherapy.
This paper references
Abstract CT105: MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): Antitumor activity and association with tumor PD-L1 expression
L. Gandhi (2014)
Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1)
V. Velcheti (2013)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells
C. Jackaman (2009)
Tremelimumab for patients with Chemotherapyresistant advanced malignant mesothelioma : an open - label , single arm , phase 2 trial
L Calabro (2013)
Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma.
M. Anraku (2008)
Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience.
R. Flores (2005)
A phase Ib study of MK3475in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck cancer
T Seiwert (2014)
A. DE GASPERIS (1950)
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
J. Hamanishi (2007)
Dual Control of Antitumor CD8 T Cells through the Programmed Death-1/Programmed Death-Ligand 1 Pathway and Immunosuppressive CD4 T Cells: Regulation and Counterregulation1
A. Currie (2009)
Phase I/II trial of PD-1 antibody nivolumab with peptide vaccine in patients naive to or that failed ipilimumab.
J. Weber (2013)
A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.
R. Herbst (2013)
Localised spontaneous regression in mesothelioma -- possible immunological mechanism.
B. Robinson (2001)
PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells
H. Soliman (2014)
A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancer.
T. Seiwert (2014)
PTEN expression is a strong predictor of survival in mesothelioma patients.
I. Opitz (2008)
Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers
R. Hassan (2010)
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
J. Brahmer (2012)
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
G. Freeman (2000)
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
J. Taube (2014)
618: Costimulatory B7-H1 In Renal Cell Carcinoma Patients: Indicator of Tumor Aggressiveness and Potential Therapeutic Target
R. H. Thompson (2005)
Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma
Rezaul Karim (2009)
B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression
J. Konishi (2004)
International Uniona Against Cancer. TNM classification of Malignant Tumors seventh edition
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
M. Sznol (2013)
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)
CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection
N. Yamada (2010)
Inhibitory B7-family molecules in the tumour microenvironment
W. Zou (2008)
Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: Prognostic correlations
O. Rena (2011)
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.
R. H. Thompson (2004)
CD8+ tumorinfiltrating lymphocytes predict favorable prognosis in malignant pleural mesotheleioma after resection
N Yamada (2010)
Antitumor activity of anti‐C‐ERC/mesothelin monoclonal antibody in vivo
K. Inami (2010)
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
S. Topalian (2012)
Prolonged survival due to spontaneous regression and surgical excision of malignant mesothelioma.
John E Pilling (2007)
Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.
S. Neragi-Miandoab (2008)
Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
R. Kreitman (2009)
Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer
Yuichiro Ohigashi (2005)
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.
S. Strome (2003)
WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer
L. Krug (2010)
In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
K. Schalper (2014)
B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis
A. Mansfield (2014)
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
O. Hamid (2013)
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
M. D. de Perrot (2009)
Apparent spontaneous complete regression of a multifocal malignant mesothelioma of the pleura
R. K. Allen (2007)
Lymphocytic infiltration of pleural mesothelioma and its significance for survival.
R. Leigh (1982)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
A. Parsa (2007)
PD-1 and its ligands in tolerance and immunity.
M. Keir (2008)
MK3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer: antitumor activity and association with tumor PD-L1 expression in NSCLC
L Gandhi (2014)
Programmed death ligand-1 expression in non-small cell lung cancer
V. Velcheti (2014)
Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma.
G. Ceresoli (2001)
This paper is referenced by
Novel systemic therapy against malignant pleural mesothelioma.
M. R. Mancuso (2017)
PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC
M. Ameratunga (2016)
PD-L1 Testing for Immune Checkpoint Inhibitors in Mesothelioma: For Want of Anything Better?
S. Lantuéjoul (2017)
Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data
Pauline du Rusquec (2019)
Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
S. Cedrés (2016)
Optimal Therapy of Advanced Stage Mesothelioma
M. Disselhorst (2017)
Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma
T. Watanabe (2018)
Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma
N. Sobhani (2019)
Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients
Paulino Tallón de Lara (2018)
Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies
A. Bononi (2015)
Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
S. Inaguma (2018)
Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma
N. S. Patil (2018)
Inhibition of yes‐associated protein down‐regulates PD‐L1 (CD274) expression in human malignant pleural mesothelioma
P. Hsu (2018)
Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis
R. Carosio (2020)
Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
S. Brosseau (2019)
Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation
A. Tsao (2018)
Prognostic value of tumor PD‐L1 expression combined with CD8+ tumor infiltrating lymphocytes in high grade serous ovarian cancer
Q. Wang (2017)
Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
N. van Zandwijk (2017)
Clinical staging of malignant pleural mesothelioma: current perspectives
M. Bonomi (2017)
Tissue and Circulating Biomarkers in Mesothelioma
Paolo Andrea Zucali (2019)
The mechanisms tumor cells utilize to evade the host's immune system.
Nyanbol Kuol (2017)
Novel insights into the pathophysiology and treatment of malignant pleural mesothelioma
Alistair M. Cook (2015)
Clinical significance of histologic subtyping of malignant pleural mesothelioma.
L. Brčić (2020)
Application of immunohistochemistry in diagnosis and management of malignant mesothelioma.
D. Chapel (2020)
Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma
Licun Wu (2016)
The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
G. Chu (2019)
Prognosis of patients with malignant mesothelioma by expression of programmed cell death 1 ligand 1 and mesothelin in a contemporary cohort in Finland.
D. Vizcaya (2020)
Immune checkpoint inhibitors in thoracic malignancies: Review of the existing evidence by an IASLC expert panel and recommendations.
J. Remon (2020)
Radiation Therapy in Mesothelioma
J. Willmann (2019)
Chemotherapy for Malignant Pleural Mesothelioma: Past, Present and Future
A. Scherpereel (2017)
M. Robert (2019)
Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
L. Cantini (2020)See more